Review: Dendritic cell immunotherapy for melanoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 1, 1999, Pages 11-22

  Hadzantonis, May ^a   O'Neill, Helen ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL VIABILITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HELPER CELL; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY COMPLEX; HUMAN; MELANOMA; PRIORITY JOURNAL; SKIN CARCINOGENESIS; ULTRAVIOLET B RADIATION;

EID: 0032897554     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.11     Document Type: Article

References (66)

1. Rossi CR, Foletto M, Vecchiato A, Alessio S, Menin N and Lise M. Management of cutaneous melanoma MO: State of the art and trends. Eur J Cancer 1997;33:-2302.
2. Mitchell MS. Immunotherapy of melanoma. J Invest Dermatol Symp Proc 1996;1:215.
3. Steinman RM. The dendritic cell system and its role in immunogenicity. Annual Rev Immunol 1991;9:271.
4. Grabbe S and Granstein RD. Presentation of tumor antigens by Langerhans cells and other dendritic cells. In Heidrun M (ed.) The immune functions of epidermal Langerhans cells, RG Landes Co., Austin, Texas, 1995, p. 141.
5. Parmiani G. Tumor immunity as autoimunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol Today 1993;14:536.
6. Klein-Szanto AJP. Pathology of human and experimental skin tumors. In Conti CJ, Slaga TJ and Klein-Szanto AJP. (eds.) Carcinogenesis - A comprehensive survey volume 11, Skin tumors: Experimental and clinical aspects, Raven Press, New York, 1989, p. 19.
7. Kamb A. Human Melanoma Genetics. J Inves Dermatol Symp Proc 1996;1:177.
8. Morison WL. Effects of ultraviolet radiation on the immune system in humans. Photochem Photobiol 1989;50:515.
9. Streilein JW, Taylor JR, Vincek V, Kurimoto I, Richardson J, Tie C, Medema JP and Golomb C. Relationship between ultraviolet radiation induced immunosuppression and carcinogenesis. J Invest Dermatol 1994;103(5 suppl.): 107S.
10. Kimber I and Cumberbatch M. (1995) Langerhans cell migration: Initiation and regulation. In Heidrun, M. (ed.) The immune functions of epidermal Langerhans cells, RG Landes Co., Austin, Texas, 1995, p. 103.
11. Nishigori C, Yarosh DB, Donawho C and Kripke ML. The immune system in ultraviolet carcinogenesis. J Investig Dermatol Symp Proc 1996;1:143.
12. Grabbe S, Beissent S, Schwarz T and Granstein RD. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy. Immunol Today 1995;16:117.
13. Kimber I and Cumberbatch M. Contemporary issues in toxicology: Dendritic cells and cutaneous immune responses to chemical allergens. Toxicology and Applied Pharmacology 1992;177:137.
14. Neale R, Russell A, Muller HK and Green A. Sun exposure, sunscreen and theIR effects in epidermal Langerhans cells. Photochem Photobiol 1997;66:260.
15. Boon T, Coulie PG and Van der Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18:267.
16. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:175.
17. Anichini A, Mortarini R, Maccalli C, Squarcina P, Fleischauer K, Mascheroni L and Parmiani G. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 1996;156:-208.
18. Nagai H, Hayashi Y, Wang E, Kako S, Horikawa T, Hayashibe K and Ichihashi M. Tissue distribution of a melanoma-associated antigen D-1 immunogenic in patients with melanoma. J Dermatol Sci 1998;17:115.
19. Boon T, Gerottini JC, Van der Eynde B, Van der Bruggen P and Van Pel A. Tumor antigens recognized by T lymphocytes. Annual Rev Immunol 1994;12:337.
20. Jäger E, Ringhoffer M, Karbach J, Arand M, Oesch F and Knuth A. Inverse relationship of melanocyte differentation antigen expression in melanoma tissues and CD8+ cytotoxic T cells responses evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996;66:470.
21. Bakker ABH, Marland G, de Boer AJ, Huijbens RJF, Danen EHJ, Adema GJ and Figdor CG. Generation of anti-melanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995;55:5330.
22. Enk AH, Jonuleit H, Saloga J and Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997;73:309.
23. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Berg G and Schadendorf D. Vaccination of melanoma patients with peptide or tumor lysatepulsed dendritic cells. Nat Med 1998;4:328.
24. Soruri A, Fayyazi A, Gieseler R, Schlott T, Runger TM, Neumann C and Peters JH. Specific autologous anti-melanoma T Cell response in vitro using monocyte-derived dendritic cells. Immunobiol 1998;198:527.
25. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J and Mauri F. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995;92:8078.
26. Ribas A, Butterfield LH, Mc Bride WH, Jilani SM, Bui LA, Vollmer CM, Lau R, Dissette VB, Hu B, Chen AY, Glaspy JA and Ecomomou JS. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovIRus-transduced murine dendritic cells. Cancer Res 1997;57:2865.
27. Celluzzi CM and Falo Jr, LD. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J Invest Dermatol 1997;108:716.
28. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman PM and Schluer G. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83.
29. Meierhoff G, Krause SW and Andreesen R. Comparative analysis of dendritic cells derived from blood monocytes or CD34+ Hematopoietic Progenitor cells. Immunobiol 1998;198:501.
30. Sallusto F and Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-α. J Exp Med 1994;179:1109.
31. Banchereau J and Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245.
32. Schuler G and Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997;186:183.
33. Gabrilovich DI, Nadaf S, Corak J, Berzosky JA and Carbone DP. Dendritic cells in antitumor immune responses H. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996;170:111.
34. Ebner S, Lenz A, Reider D, Fritsch P, Schuler G and Romani N. Expression of maturation-/migration-related molecules on human dendritic cells from blood and skin. Immunobiol 1998;1998:568.
35. Armstrong TD, Pulaski BA and Ostrand-Rosenberg S. Tumor antigen presentation: changing the rules. Cancer Immunol Immunother 1998;46:70.
36. Cohen PJ, Cohen PA, Rosenberg SA, Katz SI, and Mule JJ. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur J Immunol 1994;24:315.
37. Porgador A and Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995;182:255.
38. Chen W, Carbone FR and McCluskey J. Electro poration and commercial liposomes deliver soluble protein into the MHC class I presentation pathway: Priming in vitro and in vivo for class I-restricted recognition of soluble protein. J Immunol Methods 1993; 160:49.
39. Fields RC, Shimizu K and Mule JJ. Murine dendritic cells pulsed with while tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998;95:9482.
40. Pamer E and Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998;16:323.
41. Romani N and Schuler G. The immunologic properties of epidermal Langerhans cells as part of the dendritic cell system. Springer Semin Immunopathol 1992; 13:265.
42. Carbone FR and Bevan MJ. Class I-restricted processing and presentation of exogenous cell-associated antigen in viv
43. Falo Jr, LD, Kovacsovics-Bankowski M, Thompson K and Rock KL. Targeting antigen into the phagocytic pathway in vivo induces protective tumor immunity. Nat Med 1995;1:649.
44. Martinez-Kinader B, Lipford GB, Wagner H and Heeg K. Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway. Immunol 1995;86:287.
45. Walker C, Selbe M, Erickson A, Cataldo D, Valensi J-P and Van Nest G. Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc Natl Acad Sci USA. 1992;89:7915.
46. Raychaudhuri S, Tonks M, Carbone F, Ryskamp T, Morrow WJW and Hanna K. Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. Proc Natl Acad Sci USA 1992;89:8308.
47. Nair SK, Snyder D,Rouse BT and Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997;70:706.
48. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT and Falo Jr, LD. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 1996;183:283.
49. Kershaw MH, Trapani JA and Smyth MJ. Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Ther Immunol 1995;2:173.
50. Dalerba P, Ricci A, Russo V, Rigatti D, Nicotra MR, Mottolese M, Bordignon C, Natali PG and Traversari C. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous métastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int J Cancer 1998;77:200.
51. Gilboa E, NaIR SK and Lyerty K. Immunotherapy of cancer with dendritic-cell based vaccines. Cancer Immunol lmmunother 1998;46:82.
52. Shields MJ, Kubota R, Hodgson W, Jacobson S, Biddison WE and Ribaudo RK. The effect of human beta2-microglobulin on major histocompatibility complex I peptide loading and the engineering of a high affinity variant. Implications for peptide-based vaccines. J Biol Chem 1998;273:28010.
53. York IA and Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 1996;14:369.
54. Tüting T, Wilson CC, Martin DM, Kasamon YL, Rowles J, Ma DI, Slingluff Jr GL, Wagner SN, van der Bruggen P, Baar J, Lotze MT and Walter JS. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α.J Immunol 1998;160:1139.
55. Song W, Kong H-L, Carpenter H, Torii H, Granstein R, Rafii S, Moore MAS and Crystal RG. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186:1247.
56. Farzaneh F, Trefer N, Sterry W and Walden P. Gene therapy of cancer. Immunol Today 1998;19:294.
57. Boczkowski D, Nair SK, Snyder D and Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184:465.
58. Condon C, Watkins SC, Celluzzi CM, Thompson K and Falo Jr LD. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996;2:1122.
59. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD and Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177.
60. Celluzzi CM and Falo Jr LD. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998;160:3081.
61. Gong J, Chen D, Kashiwaba M and Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1991; 3:558.
62. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT and Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T Cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87.
63. Parmiani G. Tumour immunity as autoimmunity: tumour antigens include normal slf proteins which stimulate anergic peripheral T cells. Immunol Today 1993;14:536.
64. Zitvogel L, Couderc B, Mayordomo JI, Robbins PD, Lotze MT and Storkus WJ. IL-12-engineering dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann N Y Acad Sci 1996;795:284.
65. Esche C, Subbotin VM, Maliszewski C, Lotze MT and Shurin MR. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 1998;58:380.
66. Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R and Granstein RD. Tumor antigen presentation by murine epidermal cells. J Immunol 1991;146:3656.